PRO CAR-201B

N/A

Report date: 2025/07/08 10:33:49

Base Information

Drug NamePRO CAR-201B

Drug Alias NamePRO CAR-201B

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-STEAP1

TargetsSix-transmembrane epithelial antigen of the prostate 1

Therapy Area/IndicationsSarcoma, Ewing

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFred Hutchinson Cancer Research Center

China Registration ClassN/A

Develop Information

Active CompaniesPromiCell Inc

Inactive CompaniesN/A

Active IndicationsSarcoma, Ewing

Inactive IndicationsN/A

Other Information

ATC CodeN/A